SCHEMBL928382

SCHEMBL928382

COc1cccc(N2CC3CN(C(=O)OC(C)(C)C)CC3C2)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.53
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ABCB1 P08183 1/20 0.45
ROCK2 O75116 1/20 0.44
PDE10A Q9Y233 2/20 0.44
ALDH1A1 P00352 1/20 0.44
USP30 Q70CQ3 1/20 0.43
NR1H2 P55055 2/20 0.43
NR1H3 Q13133 1/20 0.43
TGFBR1 P36897 1/20 0.43
STS P08842 1/20 0.43
PDE4B Q07343 1/20 0.42
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20511423 0.86 GPR119 (0.70) GPR119TP53MAPTMEN1KMT2A
SCHEMBL20511395 0.86 ALDH1A1 (0.52) GPR119MAPTALDH1A1NR1H2STS
SCHEMBL10111733 0.84 GPR119 (0.67) GPR119PDE10AUSP30NR1H2
SCHEMBL15596306 0.84 GPR119 (0.67) GPR119PDE10AUSP30NR1H2
SCHEMBL2385957 0.83 ABCB1 (0.59) GPR119TP53MAPTMEN1KMT2A
SCHEMBL29556504 0.83 ABCB1 (0.59) GPR119TP53MAPTMEN1KMT2A
SCHEMBL20510744 0.83 GPR119 (0.48) GPR119NR1H2NR1H3
SCHEMBL650343 0.83 CHRNB2 (0.53) GPR119ALDH1A1NR1H2PDE4B
SCHEMBL650344 0.83 CHRNB2 (0.53) GPR119ALDH1A1NR1H2PDE4B
SCHEMBL17197316 0.83 ADRB1 (0.47) MAPTMEN1KMT2AALDH1A1MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577251-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2026-03-17 US disclosed
US-12338245-B2 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents Temple University—Of the Commonwealth System of Higher Education (US) 2025-06-24 US disclosed
EP-3600290-B1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE UNIV TEMPLE (US) 2025-06-04 EP disclosed
US-20240300954-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-09-12 US disclosed
US-20240300953-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-09-12 US disclosed
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-21 US disclosed
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-21 US disclosed
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-21 US disclosed
US-11807642-B2 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-07 US disclosed
US-11807642-B2 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-07 US disclosed
EP-3600290-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE Temple University - Of The Commonwealth System of Higher Education (US) 2020-02-05 EP disclosed
EP-3600289-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS Temple University - Of The Commonwealth System of Higher Education (US) 2020-02-05 EP disclosed
WO-2018175188-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-09-27 WO disclosed
WO-2018175190-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-09-27 WO disclosed
EP-2316836-A1 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors Abbott Laboratories (US) 2011-05-04 EP disclosed
US-7872010-B2 Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors ABBOTT LABORATORIES (US) 2011-01-18 US disclosed
US-20080275048-A1 Substituted Diazabicycloalkane Derivates ABBOTT LABORATORIES (US) 2008-11-06 US disclosed
US-7399765-B2 Substituted diazabicycloalkane derivatives ABBOTT LABORATORIES (US) 2008-07-15 US disclosed
US-20050101602-A1 For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease ABBVIE INC. 2005-05-12 US disclosed
US-20050065178-A1 Substituted diazabicycloakane derivatives ABBOTT LABORATORIES 2005-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11807642-B2 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents HTR7, HTR6, HTR5A GPR119 48/4885TP53 4469/4885MAPT 912/4885
US-20050065178-A1 Substituted diazabicycloakane derivatives CHRNA7, CHRNA1, CHRNA5 GPR119 69/4885TP53 4553/4885MAPT 3532/4885
US-20080275048-A1 Substituted Diazabicycloalkane Derivates CHRNA7, CHRNA1, CHRNA2 GPR119 84/4885TP53 4514/4885MAPT 3323/4885
US-20240300953-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS HTR7, HTR6, HTR5A GPR119 48/4885TP53 4469/4885MAPT 912/4885
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use SIGMAR1, TMEM97, OPRM1 GPR119 61/4885TP53 4861/4885MAPT 2238/4885
US-20240300954-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 GPR119 25/4885TP53 4865/4885MAPT 2638/4885
US-12338245-B2 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents HTR7, HTR6, HTR5A GPR119 48/4885TP53 4469/4885MAPT 912/4885
US-20050101602-A1 For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease CHRNA7, CHRNA2, CHRNA6 GPR119 401/4885TP53 3561/4885MAPT 333/4885
US-12577251-B2 Modulators of the sigma-2 receptor and their method of use SIGMAR1, CHRNA6, NR3C2 GPR119 108/4885TP53 4883/4885MAPT 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.